NCT01137071终止2 期
A Phase II Trial of Hu3S193 Consolidation Therapy for Patients With Relapsing Platinum-sensitive Ovarian, Primary Peritoneal and Fallopian Tubes Adenocarcinoma, Who Achieved a Second Complete Response
Recepta Biopharma16 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2011年4月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 29
- 试验地点
- 16
- 主要终点
- 1-year PFS2 Rate After the Beginning of Rescue Platinum-based Chemotherapy
研究概览
简要总结
RATIONALE: Monoclonal antibodies, such as Hu3S193, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
PURPOSE: This phase II trial is studying how well Hu3S193 works as a consolidation therapy for women with relapsing platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer.
详细描述
This is a phase II multicenter trial with Hu3S193 as a single agent in a consolidation strategy in patients with relapsing platinum-sensitive ovarian, primary peritoneal and fallopian tubes cancer who achieve a second Complete Response after a platinum-based chemotherapy after platinum-based chemotherapeutical regimen. Fifty-one (51) patients with relapsing platinum-sensitive ovarian, primary peritoneal or fallopian tubes adenocarcinoma will receive doses of 30 mg/m2 of Hu3S193 as a single agent every two weeks, in a total of 12 doses (treatment period duration: 23 weeks). After the treatment period, patients will be evaluated every 3 months for the first two years, and every 6 months for more 3 years, and then in an annual-basis until disease progression or death, whichever happens first.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •The Informed Consent Form (ICF) must be signed before the performance of any study specific procedure or treatment.
- •Female patients of >= 18 years of age.
- •Relapsing ovarian adenocarcinoma, fallopian tubes or primary peritoneal who achieved a complete clinical response after the first treatment of relapse with platinum-based regimen. A complete response is defined as the absence of cancer related symptoms, normal physical exam, normal CA-125 (tumor marker) level, normal chest X-ray and CT-scan of abdomen/pelvis. Eligibility allows the presence of nonspecific findings as long as not showing clear evidence of disease such as: lymph node and/or soft tissue abnormalities <= 1.0 cm which are frequently present on the pelvis and will not be considered to be a conclusive evidence of disease.
- •Expression of antigen Ley documented by immunohistochemistry of archived primary or metastatic tumor samples.
- •The patient must have been submitted at least to hysterectomy and bilateral salpingo-oophorectomy before entering the study and must have received platinum-based chemotherapy as adjunctive or neo-adjunctive treatment at the first presentation.
- •At least 5 and no more than 8 cycles of platinum combination therapy (i.e. doublet) as treatment for the first relapse.
- •All side effects from chemotherapy must have been resolved or must be grade
- •Interval between the last dose of the treatment with platinum that achieved clinical CR (complete response) and the first dose of Hu3S193 =< 8 weeks.
- •Karnofsky performance status >= 70%.
- •Results of laboratorial exams in the first 2 weeks before drug infusion within the following values:
- •Absolute Neutrophil Count >= 1.5 x 10x3 / mm3
- •Platelet count >= 100 x 10x3 / mm3
- •Blood bilirubin <= 2.0 mg/dL
- •Aspartate aminotransaminase (AST) and Alanine aminotransferase (ALT) <= 2.5 x upper limit of normal (ULN).
- •Blood creatinine <= 2.0 mg/dL.
- •Prothrombin time < 1.3 x control
- •Expected survival >= 12 months.
- •Patients must be willing to participate and be able to comply with the protocol throughout the study.
排除标准
- •Mucinous or clear cell histology.
- •Patients must not have received Bevacizumab as part of their treatment on relapse.
- •Diagnosis of primary tumor relapse made exclusively based on elevated levels of serum CA-125 with values <2-fold the upper limit of normality.
- •Concomitant use of systemic corticosteroids or immunosuppressive agents.
- •Known CNS (central nervous system) involvement by tumor.
- •Clinically significant heart disease (New York Heart Association Class III or IV).
- •ECG indicating clinically significant arrhythmia.
- •History of myocardial infarction within 6 months.
- •Other serious diseases, (e.g.: serious infections requiring antibiotics, bleeding disorders, chronic inflammatory bowel disease, or diseases that may interfere in the obtainment of accurate study results).
- •Radiotherapy treatment, radiopharmaceuticals (e.g. 32P), biological therapy, anti-estrogen therapy (including tamoxifen), immunotherapy or surgery within 4 weeks before the first administration of investigational product fail to recover from toxic effects of any of these therapies within 6 weeks prior to study inclusion.
- •Exposure to any investigational product within 4 months prior to study inclusion.
- •Previous treatment with a humanized murine antibody and/or fragment of such antibody.
- •Previous history of tumor (excluding appropriately treated non-melanoma skin cancer or carcinoma in situ of the cervix or no evidence of disease within at least 5 years for previous breast cancer or stage I endometrial cancer).
结局指标
主要结局
1-year PFS2 Rate After the Beginning of Rescue Platinum-based Chemotherapy
时间窗: 1-Year - From platinum-based rescue chemotherapy start date until documented disease progression or death of any cause whichever occurred first.
PFS2 is defined by the interval from the beginning of rescue platinum-based chemotherapy until documented disease progression or death for any cause while the patient was under study or during the prolonged follow-up period. Disease progression is defined by appearance of any new lesion (measurable and non-measurable) by the RECIST criteria. Disease progression date is the date when a new lesion is documented.
次要结局
- Two-year Overall Survival Rate(2-year overall survival rate after the beginning of rescue platinum-based chemotherapy.)
- Incidence of Adverse Events (AEs) - Infections and Infestations; Gastrointestinal Disorders(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Cardiac Disorders; General Disorders and Administration Site Conditions; Respiratory, Thoracic and Mediastinal Disorders (Chest Pain)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Immune System Disorders; General Disorders and Administration Site Conditions; Injury, Poisoning and Procedural Complications (Infusion Related Reaction)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Gastrointestinal Disorders(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Blood and Lymphatic System Disorders (Anaemia)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - General Disorders and Administration Site Conditions; Musculoskeletal and Connective Tissue Disorders (Chills)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Skin and Subcutaneous Tissue Disorders(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Musculoskeletal and Connective Tissue Disorders; General Disorders and Administration Site Conditions; Nervous System Disorders (Spinal Pain)(From the first infusion of medication to 30 days after the last one)
- 1-year Disease Progression-free Survival Rate(1 year from the beginning of platinum-based rescue chemotherapy start date)
- Safety - Vital Signs - Respiratory Rate(Baseline, week 2, week 4 and week 27)
- Incidence of Adverse Events (AEs) - Immune System Disorders(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Investigations(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Psychiatric Disorders (Anxiety)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Hepatobiliary Disorders; Injury, Poisoning and Procedural Complications (Hepatotoxicity)(From the first infusion of medication to 30 days after the last one)
- Safety - Vital Signs - Systolic and Diastolic Blood Pressure(Baseline, week 2, week 4 and week 27)
- Safety - Vital Signs - Temperature(Baseline, week 2, week 4 and week 27)
- Incidence of Adverse Events (AEs) - General Disorders and Administration Site Conditions(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Nervous System Disorders(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Infections and Infestations; Respiratory, Thoracic and Mediastinal Disorders(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Ear and Labyrinth Disorders(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Immune System Disorders; Respiratory, Thoracic and Mediastinal Disorders(From the first infusion of medication to 30 days after the last one)
- Safety - Vital Signs - Heart Rate(Baseline, week 2 , week 4 and week 27)
- Incidence of Adverse Events (AEs) - Musculoskeletal and Connective Tissue Disorders(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Respiratory, Thoracic and Mediastinal Disorders(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Vascular Disorders(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Eye Disorders (Ocular Hyperaemia)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Ear and Labyrinth Disorders; Nervous System Disorders (Vertigo)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Gastrointestinal Disorders; Vascular Disorders (Anal Haemorrhage)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - General Disorders and Administration Site Conditions; Injury, Poisoning and Procedural Complications (Hyperthermia)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Nervous System Disorders; Psychiatric Disorders; Respiratory, Thoracic and Mediastinal Disorders (Hoarseness)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Skin and Subcutaneous Tissue Disorders; Infections and Infestations (Tinea Pedis)(From the first infusion of medication to 30 days after the last one)
- Incidence of Serious Adverse Events (SAEs) - Gastrointestinal Disorders(From the first infusion of medication to 30 days after the last one)
- Overall Mean Pharmacokinetic (PK) Data (Minimum and Maximum Concentrations)(Predose and Postdose on weeks 1, 2, 3, 4, 5, 7 and 9)
- Incidence of Adverse Events (AEs) - Musculoskeletal and Connective Tissue Disorders; Injury, Poisoning and Procedural Complications(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Renal and Urinary Disorders; Infections and Infestations (Urinary Tract Infection)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Reproductive System and Breast Disorders (Vulvovaginal Dryness)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Gastrointestinal Disorders; Infections and Infestations; Respiratory, Thoracic and Mediastinal Disorders (Pharyngitis)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - General Disorders and Administration Site Conditions; Injury, Poisoning and Procedural Complications (Catheter Site Inflammation)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Infections and Infestations; Renal and Urinary Disorders (Urinary Tract Infection Bacterial)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Musculoskeletal and Connective Tissue Disorders; General Disorders and Administration Site Conditions; Renal and Urinary Disorders (Flank Pain)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Psychiatric Disorders; Nervous System Disorders (Insomnia)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Psychiatric Disorders (Depression)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Infections and Infestations; Respiratory, Thoracic and Mediastinal Disorders (Bronchitis)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Investigations (Blood Cholesterol Increased)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Skin and Subcutaneous Tissue Disorders; Reproductive System and Breast Disorders (Vulvovaginal Pruritus)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Renal and Urinary Disorders (Dysuria)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Respiratory, Thoracic and Mediastinal Disorders; Cardiac Disorders (Dyspnoea)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Skin and Subcutaneous Tissue Disorders; Injury, Poisoning and Procedural Complications(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Cardiac Disorders; Vascular Disorders; Nervous System Disorders (Dizziness)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Endocrine Disorders; Metabolism and Nutrition Disorders (Hyperglycaemia)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Gastrointestinal Disorders; Reproductive System and Breast Disorders; Renal and Urinary Disorders (Pelvic Pain)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Immune System Disorders; Blood and Lymphatic System Disorders; Injury, Poisoning and Procedural Complications (Transfusion Reaction)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Vascular Disorders; Gastrointestinal Disorders (Haemorrhoids)(From the first infusion of medication to 30 days after the last one)
- Incidence of Adverse Events (AEs) - Vascular Disorders; Respiratory, Thoracic and Mediastinal Disorders (Epistaxis)(From the first infusion of medication to 30 days after the last one)
- Two-year Overall Survival: Median Time to Death(2-year overall survival rate after the beginning of rescue platinum-based chemotherapy.)
- Incidence of Serious Adverse Events (SAEs) - Musculoskeletal and Connective Tissue Disorders - Hip Fracture(From the first infusion of medication to 30 days after the last one)
研究者
研究点 (16)
Loading locations...
相似试验
已完成
2 期
Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerFallopian Tube CancerOvarian CancerPrimary Peritoneal CancerNCT00617773Recepta Biopharma31
已完成
1 期
Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)Lung CancerNCT00084799Ludwig Institute for Cancer Research10
已完成
3 期
Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT00275054German CLL Study Group825
已完成
1 期
Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed NeuroblastomaNeuroblastomaNCT00450307Memorial Sloan Kettering Cancer Center32
终止
2 期
Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast CancerBreast CancerNCT00118053University of Medicine and Dentistry of New Jersey5